p yap1  (Cell Signaling Technology Inc)

Journal: Journal of Translational Medicine

Article Title: TROP2 confers resistance to oxidative stress-induced cancer cell death through YAP/HMOX1 signaling

doi: 10.1186/s12967-026-07955-z

Figure Lengend Snippet: TROP2 suppression sensitized NSCLC to RSL3-induced ferroptosis in vivo. ( A ) Schematic diagram of the in vivo experimental timeline. Nude mice were subcutaneously injected with control (shCON) or TROP2-knockdown (shTROP2) PC9 cells, followed by intraperitoneal injection of RSL3 (5 mg/kg) or vehicle every other day. ( B ) Representative photographs of dissected subcutaneous tumors from each treatment group at the endpoint of the study. ( C ) Final tumor weights from each group at the endpoint. Data are presented as mean ± SD ( n = 6). ( D ) Tumor growth curves showing tumor volume over time for the four experimental groups. Data are presented as mean ± SEM ( n = 6 mice per group). ( E ) Representative IHC images of tumor sections stained for TROP2, YAP1, HMOX1, ACSL4, and SLC7A11 from the indicated groups. Scale bar, 100 μm. Data are presented as mean ± SD ( n = 6, C) or mean ± SEM ( n = 6 mice per group, D ). Statistical significance for differences among groups was determined by one-way ANOVA followed by Tukey’s post hoc test (C, and for the final time point in D). ∗ P < 0.05, ∗∗ P < 0.01

Article Snippet: After that, the membranes were blocked in 5% fat-free milk for 1 h. The membranes were incubated with the primary antibodies including TROP2 (1:1000, cat #47866, CST), GPX4 (1:1000, cat #AF7020, Beyotime), SLC7A11 (1:1000, cat #AF7992, Beyotime), ACSL4 (1:1000, cat #AG1908, Beyotime), HMOX1 (1:1000, cat #AG2181, Beyotime), YAP1 (1:1000, cat #14074, CST), P-YAP1 (1:1000, cat #13619, CST), LATS1 (1:1000, cat #3477, CST), p-LATS1 (1:1000, cat #9157, CST), Histone3 (1:1000, cat #9715, CST),α-Tubulin (1:1000, cat #2144, CST) at 4 °C overnight and the secondary antibodies at room temperature for 2 h. Protein bands were visualized using the ECL (Bio-Rad, Hercules, CA, USA).

Techniques: In Vivo, Injection, Control, Knockdown, Staining

Journal: Journal of Translational Medicine

Article Title: TROP2 confers resistance to oxidative stress-induced cancer cell death through YAP/HMOX1 signaling

doi: 10.1186/s12967-026-07955-z

Figure Lengend Snippet: TROP2 confers ferroptosis resistance by inactivating YAP to suppress HMOX1 transcription. ( A ) YAP1 mRNA levels in H292 and PC9 cells with TROP2 knockdown, as determined by qRT-PCR. ( B ) YAP1 mRNA levels in PC9 and A549 cells with TROP2 overexpression, as determined by qRT-PCR. ( C ) Representative IF images showing enhanced nuclear localization of YAP (green) in PC9 cells upon TROP2 knockdown. Nuclei were stained with DAPI (blue). Scale bar, 50 μm. ( D ) Representative IF images showing suppressed nuclear localization of YAP (green) in PC9 cells upon TROP2 overexpression. Scale bar, 50 μm. ( E ) Western blot analysis of YAP protein levels in nuclear and cytoplasmic fractions of PC9 and H292 cells with or without TROP2 knockdown. ( F ) Quantitative analysis (bar graph) of the bands was shown adjacent to the representative blots (from E). ( G, H ) Cell viability assessed by CCK-8 assay in PC9 and H292 cells with TROP2 knockdown, with or without concomitant YAP inhibition, following RSL3 treatment. ( I,J ) Measurement of cellular GSH levels in PC9 and H292 cells under the indicated conditions. ( K, L ) Measurement of cellular MDA levels in PC9 and H292 cells under the indicated conditions. Data are presented as mean ± SD ( n = 3). Statistical significance was determined by two-tailed unpaired Student’s t-test ( A , B , F ); two-way ANOVA followed by Sidak’s post hoc test or three-way ANOVA followed by Sidak’s post hoc test ( G - L ). ∗ P < 0.05, ∗∗ P < 0.01

Article Snippet: After that, the membranes were blocked in 5% fat-free milk for 1 h. The membranes were incubated with the primary antibodies including TROP2 (1:1000, cat #47866, CST), GPX4 (1:1000, cat #AF7020, Beyotime), SLC7A11 (1:1000, cat #AF7992, Beyotime), ACSL4 (1:1000, cat #AG1908, Beyotime), HMOX1 (1:1000, cat #AG2181, Beyotime), YAP1 (1:1000, cat #14074, CST), P-YAP1 (1:1000, cat #13619, CST), LATS1 (1:1000, cat #3477, CST), p-LATS1 (1:1000, cat #9157, CST), Histone3 (1:1000, cat #9715, CST),α-Tubulin (1:1000, cat #2144, CST) at 4 °C overnight and the secondary antibodies at room temperature for 2 h. Protein bands were visualized using the ECL (Bio-Rad, Hercules, CA, USA).

Techniques: Knockdown, Quantitative RT-PCR, Over Expression, Staining, Western Blot, CCK-8 Assay, Inhibition, Two Tailed Test

Journal: Journal of Nanobiotechnology

Article Title: Hyaluronic acid-based reduction responsive nanoparticles for Improved anti-psoriasis effects of traditional Chinese herb monomer oleanolic acid via blocking YAP-AREG axis

doi: 10.1186/s12951-026-04264-x

Figure Lengend Snippet: NPH modulates the YAP signaling pathway to exert anti-psoriatic effects. ( A ) IHC staining images of p-YAP1, active YAP1, and YAP1 in psoriatic lesions from different groups and ( B ) quantitative analysis of the average positive intensity of p-YAP1, active YAP1, and YAP1 in the epidermal layer of the lesions. Bar = 100 μm and 20 μm. ( C ) IF staining images of p-YAP1 and YAP1 in psoriatic lesions from different groups. Bar = 100 μm and 25 μm, and ( D ) the ratios of p-YAP1/YAP1. ( E ) Western blot analysis of Hippo/YAP pathway components in psoriatic lesions from different groups. ( F ) The ratios of p-YAP1/YAP1, p-LATS1/LATS1, and p-MST1/MST1 quantified from Fig. 8E ( n = 3). ( G ) Expression of YAP1 and YAP1-regulated genes in the psoriatic lesions from different groups by RT-qPCR. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, n.s. = no significance

Article Snippet: Skin tissues from the Normal, IMQ-PBS, and IMQ-NPH groups were subjected to double immunofluorescence staining for p-YAP1 (Abmart, T55743 , 1:1000 dilution) and YAP1 (Abmart, PAQ6610, 1:250 dilution).

Techniques: Immunohistochemistry, Staining, Western Blot, Expressing, Quantitative RT-PCR

Journal: Experimental & Molecular Medicine

Article Title: Temporal vascular pattern remodeling mediated by the FHL2/sFRP2 signaling pathway in tenocytes affects tendon repair and regeneration

doi: 10.1038/s12276-025-01574-2

Figure Lengend Snippet: a A schematic diagram of group allocation, including the normal (normal tendon, Adler blood flow grading 0–I), HypoV (chronic tendinopathy, Adler blood flow grading 0–I) and HyperV groups (chronic tendinopathy, Adler blood flow grading II–III). b Preoperative rotator cuff power Doppler imaging in the normal (Adler grading 0–I), HypoV (Adler grading 0–I) and HyperV (Adler grading II–III) groups. The yellow-colored area indicates the presence of slow blood flow, with the intensity of the color representing the signal power. The scale on the side shows the signal power range. c An illustration of upper limb resistance strength measurement. Patients maximally resisted the examiner’s downward pull while maintaining position. The maximum resistance force and duration were recorded (Supplementary Data File ). d Preoperative and postoperative (1, 3, 6 and 12 months) VAS in the HypoV and HyperV groups. e The modified UCLA shoulder function scores at each follow-up time point in the HypoV and HyperV groups. f A comparison of maximum resistance force difference (in Newtons, left axis) and resistance duration difference (in seconds, right axis) between unaffected and affected sides preoperatively and at 12 months postoperatively in the HypoV and HyperV groups. g Representative hematoxylin–eosin staining (HE), Alcian Blue staining (AB) and SR images in the normal, HypoV and HyperV groups. The black arrows indicate extensive angiogenesis (scale bar, 50 μm). h Modified Bonar scoring. i The area ratio of type III collagen (green thin fibers) to type I collagen (orange thick fibers) in SR staining. j IHC staining of VEGFA and CD34 (scale bar, 50 μm). The red arrows indicate vascular accumulation at the tendon sheath boundaries; the black arrows indicate vascular accumulation within the tendon (intratendinous). k The average optical density (AOD) for VEGFA in IHC staining. l A statistical graph for vascular density (per 0.5 mm 2 , CD34 IHC). m A principal component analysis in bulk RNA-seq. n A volcano plot of DEGs in bulk RNA-seq. o A WB for the protein expression of FHL2, YAP1 and sFRP2 was conducted on six samples from the HyperV and HypoV groups. p A statistical chart for relative protein expression in WB. q IHC staining of FHL2, YAP1 and sFRP2 (scale bar, 50 μm). r The AOD for FHL2, YAP1 and sFRP2 in IHC staining. * P < 0.05.

Article Snippet: The primary antibodies were as follows: FHL2 (TD13015, Abmart), YAP1 (A19134, ABclonal), p-YAP1 S127 (TA3328, Abmart), sFRP2 (TD4451, Abmart), type I collagen (Col-I, ab138492, Abcam), type III collagen (Col-III, TA5457, Abmart), vascular endothelial growth factor A (VEGFA, TA5131, Abmart) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, GB15002, Servicebio).

Techniques: Imaging, Modification, Comparison, Staining, Immunohistochemistry, RNA Sequencing, Expressing

Journal: Experimental & Molecular Medicine

Article Title: Temporal vascular pattern remodeling mediated by the FHL2/sFRP2 signaling pathway in tenocytes affects tendon repair and regeneration

doi: 10.1038/s12276-025-01574-2

Figure Lengend Snippet: a Treadmill exercise protocol for rats (Supplementary Data File ). b SR staining, with type III collagen (Col-III) in green and Col-I in yellow (scale bar, 50 μm). c Statistical chart of Col-III/Col-I area ratios in SR staining. d Hematoxylin–eosin (HE) staining (scale bar, 50 μm). e IHC staining for CD34, with the black arrows indicating blood vessels concentrated at the tendon sheath boundary, red arrows indicating blood vessels concentrated within the tendon (intratendinous) and blue dashed lines marking tendon edges (scale bar, 50 μm). f Vascular density in each group (CD34 IHC, per 0.5 mm 2 ). g The percentages of Ki-67 + proliferative cells (Supplementary Fig. ). h The percentages of apoptotic cells (TUNEL) (Supplementary Fig. ). i The average optical density (AOD) for VEGFA in IHC staining (Supplementary Fig. ). j IHC staining for FHL2 (scale bar, 20 μm). k IHC staining for YAP1 (scale bar, 20 μm). l IHC staining for sFRP2 (scale bar, 20 μm). m AOD for the IHC staining of FHL2, YAP1 and sFRP2. n WB of key proteins. o A statistical chart for relative protein expression levels in WB. * P < 0.05, ns: P > 0.05.

Article Snippet: The primary antibodies were as follows: FHL2 (TD13015, Abmart), YAP1 (A19134, ABclonal), p-YAP1 S127 (TA3328, Abmart), sFRP2 (TD4451, Abmart), type I collagen (Col-I, ab138492, Abcam), type III collagen (Col-III, TA5457, Abmart), vascular endothelial growth factor A (VEGFA, TA5131, Abmart) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, GB15002, Servicebio).

Techniques: Staining, Immunohistochemistry, TUNEL Assay, Expressing

Journal: Experimental & Molecular Medicine

Article Title: Temporal vascular pattern remodeling mediated by the FHL2/sFRP2 signaling pathway in tenocytes affects tendon repair and regeneration

doi: 10.1038/s12276-025-01574-2

Figure Lengend Snippet: a CD34 IHC staining, with the red arrows indicating clustered vessels (scale bar, 50 μm). b Vascular density in each group (per field, CD34 IHC). c OCTA showing the spatial distribution, morphology and abundance of vascular remodeling in the Td-Inj and Td-Sut groups, with dashed lines marking region of interest. d A statistical chart of VAD. e A statistical chart of VDI. f A statistical chart of VCI. g–j Statistical charts of average optical density (AOD) for FHL2 ( g ), YAP1 ( h ) p-YAP1 ( i ) and sFRP2 ( j ) in IHC staining. k WB of key proteins in the sham, Td-Inj and Td-Sut groups. l The relative protein expression levels measured using WB (** P < 0.05 versus sham).

Article Snippet: The primary antibodies were as follows: FHL2 (TD13015, Abmart), YAP1 (A19134, ABclonal), p-YAP1 S127 (TA3328, Abmart), sFRP2 (TD4451, Abmart), type I collagen (Col-I, ab138492, Abcam), type III collagen (Col-III, TA5457, Abmart), vascular endothelial growth factor A (VEGFA, TA5131, Abmart) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, GB15002, Servicebio).

Techniques: Immunohistochemistry, Expressing

Journal: Experimental & Molecular Medicine

Article Title: Temporal vascular pattern remodeling mediated by the FHL2/sFRP2 signaling pathway in tenocytes affects tendon repair and regeneration

doi: 10.1038/s12276-025-01574-2

Figure Lengend Snippet: a Multiplex IF staining of EdU + FHL2 + TnC + tenocytes. b The percentage of EdU + FHL2 + TnC + (proliferative, left axis) and FHL2 + TnC + (right axis) cells. c Multiplex IF of EdU + YAP1 + TnC + tenocytes. d The percentage of EdU + YAP1 + TnC + (proliferative, left axis) and YAP1 + TnC + (right axis) cells. e Multiplex IF of EdU + sFRP2 + TnC + tenocytes. f The percentage of EdU + sFRP2 + TnC + (proliferative, left axis) and sFRP2 + TnC + (right axis) cells. g Multiplex IF of EdU + sFRP2 + vWF + endothelial cells. h The percentage of EdU + sFRP2 + vWF + (proliferative, left axis) and sFRP2 + vWF + (right axis) cells. Scale bar, 20 μm.

Article Snippet: The primary antibodies were as follows: FHL2 (TD13015, Abmart), YAP1 (A19134, ABclonal), p-YAP1 S127 (TA3328, Abmart), sFRP2 (TD4451, Abmart), type I collagen (Col-I, ab138492, Abcam), type III collagen (Col-III, TA5457, Abmart), vascular endothelial growth factor A (VEGFA, TA5131, Abmart) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, GB15002, Servicebio).

Techniques: Multiplex Assay, Staining

Journal: Experimental & Molecular Medicine

Article Title: Temporal vascular pattern remodeling mediated by the FHL2/sFRP2 signaling pathway in tenocytes affects tendon repair and regeneration

doi: 10.1038/s12276-025-01574-2

Figure Lengend Snippet: a The schematic diagram of model construction. AAV- NC , AAV- YAP1 KD and AAV- YAP1 OE transfection was conducted, followed by tendon injury modeling at 6 weeks to establish Ctl/ NC , Inj/ NC , Inj/ YAP1 KD and Inj/ YAP1 OE groups. b , c Tendon samples were collected 6 and 12 weeks after AAV- YAP1 OE transfection without tendon injury modeling. The reliability of transfection was assessed by WB, with the relevant statistical results displayed in panel c . d , e Tendon samples were collected 6 and 12 weeks after AAV- YAP1 KD transfection without tendon injury modeling. The reliability of transfection was assessed by WB, with the relevant statistical results displayed in panel e . f Hematoxylin–eosin (HE) staining (scale bar, 50 μm). g Masson staining (scale bar, 50 μm). h A statistical chart of loose collagen volume fraction (%LCVF) from Masson staining. i The OCTA of tendons 6 weeks after modeling, with dashed lines showing the tendon region (region of interest). j A statistical chart of VAD. k A statistical chart of VCI. l A statistical chart of VDI. ** P < 0.05 versus Ctl/ NC .

Article Snippet: The primary antibodies were as follows: FHL2 (TD13015, Abmart), YAP1 (A19134, ABclonal), p-YAP1 S127 (TA3328, Abmart), sFRP2 (TD4451, Abmart), type I collagen (Col-I, ab138492, Abcam), type III collagen (Col-III, TA5457, Abmart), vascular endothelial growth factor A (VEGFA, TA5131, Abmart) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, GB15002, Servicebio).

Techniques: Transfection, Staining

Journal: Experimental & Molecular Medicine

Article Title: Temporal vascular pattern remodeling mediated by the FHL2/sFRP2 signaling pathway in tenocytes affects tendon repair and regeneration

doi: 10.1038/s12276-025-01574-2

Figure Lengend Snippet: a , b WB (panel a ) and statistical charts (panel b ) for the relative expression of key proteins in Ctl/ NC , Inj/ YAP1 KD and Inj/ YAP1 OE groups (** P < 0.05 versus Ctl/ NC ). c Multiplex IF staining of YAP1 + TnC + tenocytes. d Multiplex IF of sFRP2 + TnC + tenocytes. e , f The proportion of YAP1 + TnC + and sFRP2 + TnC + cells (fold to Ctl/ NC ). g Multiplex IF of CD34 + PLCB1 + ATF6 + endothelial cells. h Vascular density in each group (fold to Ctl/ NC , CD34). i The proportion of CD34 + PLCB1 + ATF6 + cells (fold to Ctl/ NC ). Scale bar, 20 μm.

Article Snippet: The primary antibodies were as follows: FHL2 (TD13015, Abmart), YAP1 (A19134, ABclonal), p-YAP1 S127 (TA3328, Abmart), sFRP2 (TD4451, Abmart), type I collagen (Col-I, ab138492, Abcam), type III collagen (Col-III, TA5457, Abmart), vascular endothelial growth factor A (VEGFA, TA5131, Abmart) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, GB15002, Servicebio).

Techniques: Expressing, Multiplex Assay, Staining